- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04020159
Global Registry for COL6-related Dystrophies
The Global Registry for COL6-related dystrophies (www.collagen6.org) is a database for individuals who have been diagnosed with Bethlem Myopathy, Ullrich Congenital Muscular Dystrophy (UCMD) or an intermediate form of these diseases. The registry team is based at the John Walton Muscular Dystrophy Research Centre at Newcastle University, UK and is part of the TREAT-NMD alliance global network of registries. The registry has been developed in partnership with a number of leading neuromuscular researchers and is funded by the Collagen VI Alliance.
This patient registry will:
- Help identify patients for relevant clinical trials as they become available
- Encourage further research into Collagen 6-related dystrophies
- Provide researchers with specific patient information to support their research
- Assist doctors and other health professionals by providing them with up-to-date information on managing Collagen 6- related dystrophies, to help them deliver better standards of care for their patients
The investigators welcome the registration of:
✓ All patients, with a diagnosis of a COL6-related dystrophy (Bethlem Myopathy, Ullrich Congenital Muscular Dystrophy or Intermediate form) , which has been confirmed via genetic testing or muscle biopsy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Global Registry for COL6-related dystrophies (www.collagen6.org) is an international registry for patients with a COL6-related condition; no experimental intervention is involved. Patients will receive information on the most up to date standards of care relating to their disease and may be invited to participate in relevant clinical trials. Their data will be updated annually and stored indefinitely, or until they request their data to be removed.
The data will be collected via a secure online form and stored on a secure server. Data collected from patients will include demographic information, diagnosis, current condition (wheelchair use and motor ability, respiratory function, contractures and scoliosis), family history and quality of life. Further information collected from patients' doctors will include genetics, age of onset, lung function, medication, muscle strength, contractures and muscle MRI findings.
One of the purposes of the Global Registry for COL6-related dystrophies is to define the patient population and disease course, therefore data is collected longitudinally and participants will be invited to update their records on a yearly basis.
Access to the database is limited to named individuals, approved by the Principal Investigator, Professor Volker Straub, and the database curator. The database is password protected, with different levels of access. All database entries and contacts are traceable through an audit trail. A SOP has been formulated to cover administration, management and communication procedures for the database.
Researchers and Industry may ask specific questions of registry data. These questions may be to support academic research, feasibility studies for clinical trials or recruitment for clinical trials. Any enquiries for data will be examined and approved by the registry steering committee. Data released for approved enquiries would be de-identified aggregate data. In the case of recruitment for clinical trials when the registry principle investigator and/or curator believe that a patient meets a trial's inclusion criterion and might benefit from participation in a trial, the patient will be contacted by the curator with general information about the upcoming trial and will be asked to contact their local trial/study centre for more information if they are interested in participating. The patient's name or any other personal information will not be given to researchers or industry. Clinical trials will need to have appropriate IRB/ethics board and steering committee approval although the registry will not endorse any particular trial.
Registry participation in voluntary and participants may decline to participate or withdraw consent for their data to be stored in the Global Registry for COL6-related dystrophies at any time without prejudice.
The protocol, patient information sheets and consent forms, and relevant supporting information has been reviewed and approved by NHS HRA Research Ethics Committee and Newcastle University ethics committee.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Sam McDonald
- Phone Number: 01912418605
- Email: collagen6registry@newcastle.ac.uk
Study Contact Backup
- Name: Sam McDonald
- Email: registries@newcastle.ac.uk
Study Locations
-
-
-
Newcastle Upon Tyne, United Kingdom
- Recruiting
- Newcastle University
-
Contact:
- Sam McDonald
- Phone Number: 0191 2418605
- Email: sam.mcdonald@newcastle.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- confirmed diagnosis of a COL6-related dystrophy (Bethlem Myopathy, Ullrich Congenital Muscular Dystrophy (UCMD), or an intermediate form of these conditions.
Exclusion Criteria:
- absence of a diagnosis of COL6-related dystrophy
- Bethlem Myopathy Type 2, Ullrich Congenital Muscular Dystrophy 2 and other COL12-related conditions
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with COL6-related dystrophy
Participants who have volunteered to participate will complete various questionnaires relating to their condition.
|
No intervention/treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient questionnaire
Time Frame: 12 months
|
Patient reported genetic diagnosis, motor and respiratory function, contractures, pain, unplanned admissions, and quality of life updated annually.
|
12 months
|
Clinician questionnaire
Time Frame: 12 months
|
Clinician reported details of current medical condition (ambulatory status, medications, comorbidities) and medical history (first presenting symptoms, age at diagnosis, diagnosis (genetic, MRI and muscle biopsy findings)), updated annually.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Volker Straub, Newcastle University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18/NE/0243
- 8451 (The Newcastle upon Tyne Hospitals NHS FT)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bethlem Myopathy
-
Ruth SalimUnknown
-
Rigshospitalet, DenmarkCompleted
-
Istituto Ortopedico RizzoliCompletedBethlem Myopathy | Ullrich Congenital Muscular DystrophyItaly
-
Newcastle-upon-Tyne Hospitals NHS TrustRecruitingX-linked Myotubular Myopathy | Centronuclear Myopathy | Myotubular Myopathy | Myotubular Myopathy 1 | Myotubular (Centronuclear) Myopathy | Centronuclear Myopathy, X-LinkedUnited Kingdom
-
Clinic for Special ChildrenRecruitingMyopathy | Myopathy; Hereditary | Myopathies, Nemaline | TNNT1-associated Myopathy | Infantile-onset Nemaline Rod Myopathy | Myopathy, Rod | Amish Nemaline Myopathy | Nemaline Myopathy 5 | NEM5 | Genetic Muscle Disease | Recessive Hereditary Disorder (Autosomal) | ANMUnited States
-
Vastra Gotaland RegionEnrolling by invitationMusculoskeletal Diseases | Neuromuscular Diseases | Centronuclear Myopathy | Nemaline Myopathy | Congenital Myopathy | Myosin Storage MyopathySweden
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyCanada, United States, Bulgaria
-
James DowlingCanadian Institutes of Health Research (CIHR); Cures Within Reach; The Joshua... and other collaboratorsRecruitingX Linked Myotubular MyopathyUnited Kingdom, Canada, United States
-
Radboud University Medical CenterUMC UtrechtNot yet recruitingCentronuclear Myopathy | Nemaline Myopathy | Central Core Disease | Multi-Minicore DiseaseNetherlands
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Clinical Trials on Patient Registry
-
Newcastle UniversityLudwig-Maximilians - University of Munich; LGMD2i Research Fund; CureLGMD2iRecruitingLimb Girdle Muscular Dystrophy | Congenital Muscular Dystrophy | LGMDR9 | LGMD2I | Walker-Warburg Syndrome | Muscle-Eye-Brain Disease | FKRP Gene MutationUnited Kingdom
-
Boston Children's HospitalBrigham and Women's HospitalRecruiting
-
Chang Gung Memorial HospitalUnknownFebrile Neutropenia | Hematological Disease | Fungal InfectionsTaiwan
-
Newcastle UniversityRoche Pharma AG; Biogen; Adult SMA REACH; SMA REACH UKRecruiting
-
Newcastle UniversityRecruiting
-
Asan Medical CenterRecruitingCervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Peritoneal CancerKorea, Republic of
-
Newcastle UniversityRecruitingFacioscapulohumeral Muscular DystrophyUnited Kingdom
-
A.O. Ospedale Papa Giovanni XXIIIRecruiting
-
Dartmouth-Hitchcock Medical CenterThe Cleveland ClinicRecruitingAmyotrophic Lateral SclerosisUnited States
-
SCRI Development Innovations, LLCWithdrawnArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipUnited States